ArticleCurrent research in pharmacology and drug discovery2025

The suppression of the SPHK1/S1P/S1PR3 signaling pathway diminishes EGFR activation and increases the sensitivity of non-small cell lung cancer to gefitinib.

Jing Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.